FilingFirehose · free AI preview
Vistagen Therapeutics, Inc.
VTGN · AI-generated SEC analysis preview · refreshes when data changes
⚠️ Red flag 8-Ks: 3
Types: Officer Departure
Vistagen Therapeutics has filed three officer departure 8-Ks in the past 90 days, signaling potential leadership instability during a critical period for a clinical-stage biotech. No cyber incidents were detected in our monitoring window, but turnover at this scale warrants deeper context around financing runway, shareholder dilution trajectory, and cash burn patterns. The full $49 Report adds a dilution risk score, complete 8-K filing context with dates and titles, 12-month financing history, and AI-detected signals around insider trading and capital structure stress.
Want the full 5-section $49 Report on VTGN?
Dilution risk score · 12 months of 8-K context · financing history · AI risk signals · bottom-line framing. Delivered in ~5 minutes.
See a real sample report →
This preview was AI-generated from FilingFirehose's SEC EDGAR ingestion pipeline.
Not investment advice. Verify all claims against original filings.